|Year : 2012 | Volume
| Issue : 3 | Page : 406-408
Incidence of gall stone formation in acromegalic patients on octreotide therapy
Aditi A Chakravarty1, Ajay Ajmani1, Smita Manchanda2, Bindu Kulshreshtha1, Shweta Chopra1
1 Department of Endocrinology, Dr. Ram Manohar Lohia Hospital, New Delhi, India
2 Department of Radiology, Dr. Ram Manohar Lohia Hospital, New Delhi, India
|Date of Web Publication||5-May-2012|
Department of Endocrinology, Dr. Ram Manohar Lohia Hospital, New Delhi
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Objective: Octreotide, a long-acting synthetic somatostatin analog, has been widely used for ac-romegalic patients. Gastrointestinal (GI) side effects and gall stones are predominant side effects. We report incidence of gall stones in our cohort of acromegalic patients treated with octreotide therapy. Design: Retrospective case observational study. Setting: Endocrinology Unit, Dr. Ram Manohar Lohia, Hospital, New Delhi. Materials and Methods: Patients of acromegaly on primary or secondary octreotide therapy. Intervention: Patients were enquired regarding complaints related to the GI system and their medical records were reviewed. Ultrasound films at various intervals while on octerotide therapy were evaluated by the radiologist for presence of sludge and development of gall stones. Results: Of seven patients, five developed gallstones and sludge was seen in three patients at intervals ranging from 11 to 36 months postoctreotide initiation. Conclusion: A high incidence of gall stone formation in the present study as compared to the West was noted, the reasons for which are not clear.
Keywords: Acromegaly, gall stones, octreotide
|How to cite this article:|
Chakravarty AA, Ajmani A, Manchanda S, Kulshreshtha B, Chopra S. Incidence of gall stone formation in acromegalic patients on octreotide therapy. Indian J Endocr Metab 2012;16:406-8
|How to cite this URL:|
Chakravarty AA, Ajmani A, Manchanda S, Kulshreshtha B, Chopra S. Incidence of gall stone formation in acromegalic patients on octreotide therapy. Indian J Endocr Metab [serial online] 2012 [cited 2021 Jun 24];16:406-8. Available from: https://www.ijem.in/text.asp?2012/16/3/406/95683
| Introduction|| |
Surgery is the primary modality of treatment in pituitary tumors characterized by GH excess. However, in about 20-40% of patients, GH levels remain high after surgery.  The use of dopamine agonists as an adjuvant medical therapy postsurgery has shown poor outcomes. Newer modalities of treatment such as somatostatin analogs and GHRH antagonist (pegvisomant) have shown encouraging results.
Octreotide, a long-acting synthetic somatostatin analog, has been widely used for acromegalic patients. Gastrointestinal (GI) side effects are the predominant complaints attributable to inhibition of GI and gall bladder motility and function. Gall stones have been reported in patients ranging from 11% to 34% in studies reported in the West. ,, To the best of our knowledge, there is no such previous report from India. We report here our experience on incidence on gall stones with octreotide therapy in acromegalic patients.
| Materials and Methods|| |
Patients with acromegaly who had received octreotide therapy for a period of at least 3 months were included in the study. All patients underwent detailed history and examination including their initial presenting complaints and present symptoms related to GIT while on octerotide therapy. Their medical records were reviewed for clinical, biochemical, hormonal details, and imaging. Ultrasound films at various intervals while on octerotide therapy were evaluated by the radiologist for presence of sludge and development of gall stones.
| Results|| |
There were seven patients, three males and four females, age ranging from 27 to 60 years. The initial presenting complaints included headache, visual disturbances, acromegalic features, and menstrual complaints. Two patients had diabetes mellitus, three were hypertensive, and one patient was hypothyroid, hypogonad, and hypocortisolemic at presentation. These patients had been symptomatic for a period ranging from 4 months to 4 years before diagnosis. Of seven patients, five had been on primary octerotide therapy, one received octreotide postsurgery, and one received octreotide postsurgery and gamma knife therapy. Postglucose GH and IGF1 levels before initiation of octreotide therapy ranged from 3.04 to 179 ng/ml and 361 to 1143 ng/ml, respectively.
These patients received octreotride therapy for a period ranging from 6 months to 13 months. All patients received monthly doses of 20 mg of long-acting octreotide (Octreotide LAR). Therapy was stopped and was restarted in three patients. Octreotride was well tolerated by all patients. IGF1 levels reduced to normal in all except three patients. There was no remission of the diabetic status in two patients with octreotide.
[Table 1] shows the profile of GI symptoms in patients while on octreotide therapy. [Table 2] shows the development of biliary sludge and gallstones in these patients.
|Table 1: Profile of the patients related to gastrointestinal symptoms while on octeotride therapy|
Click here to view
|Table 2: Shows the development of biliary sludge and gall stones in patients while on octreotide therapy|
Click here to view
| Discussion|| |
Octreotide is a long-acting synthetic somatostatin analog. It acts by binding to the somatostatin receptor subtypes 2 and 5, thereby decreasing the production growth hormone and IGF-1.  Octreotide is used as an adjuvant therapy to surgery and radiotherapy and is a preferred medical treatment in patients with acromegaly. Being a synthetic analog, its hydrolysis by the plasma peptidase is delayed which results in the desired prolonged duration of action. The drug is usually well tolerated; the most common side effects include diarrhea, abdominal discomfort, and nausea.  These side effects are usually self-limiting lasting for a period of upto 3 months after initiation of therapy.  Gall stone formation is frequent varying in prevalence from 11% to 34% in different studies.
There are a number of mechanisms contributing to the formation of gall stones, but none has been conclusively proven. Dowling laboratory were the pioneers of studies describing pathogenesis of the gall stone formation.  The bile in patients on octerotide is supersaturated in cholesterol resulting in cholesterol-rich gall stones. , Some studies have shown that such patients have impaired gall bladder contraction and prolonged small and large colonic reabsorption and transit, and increased proportion of deoxycholic acid in biliary bile acids.  Prolongation of large intestinal transit time causes increase in the number of fecal anaerobes and the activity of rate limiting enzyme pathway (7-α-dehydroxylation) which in turn increases the proportion of deoxycholic acid. It is also believed that as a result of the slow colonic transit, there is an alteration of the pH of the colon making it more alkaline, thereby resulting in excess of soluble form of deoxycholic acid.  De novo synthesis of deoxycholic acid was also found to be increased in patients receiving octreotide by Bathgate et al. Apart from the cholesterol supersaturation, octreotide administration is known to interfere with biliary tract motility due to inhibition of choleocystokinin release from the small intestine. , Additionally, octretotide administration inhibits the postprandial relaxation of the sphinter of Oddi. 
New gallstone formation has been reported in upto 34% of patients treated with depot somatostatin analogs. ,, Attansio et al. found that among 62 patients on LAN 60 (long acting somatostain analog) treatment, 12 had preexisting gallstones and 10 patients (11%) developed new biliary abnormalities (sludge or stones) while on treatment.  Catnach et al. reported gall stones in 34% of the 39 patients receiving octreotide.  However, another study reported a very high incidence of gallstones in six out of seven patients within 8 months of therapy.  Serial ultrasound scanning at 6-month interval for formation and progression of gall stones on somatostatin analogs was performed by Ayuk et al. They observed that in 4 of 22 subjects, gallstones developed 24-40 months after commencing treatment with long-acting somatostatin analogs and persisted throughout the study period, whereas in the remaining 1 subject gallstones were identified 2 months into the study period and steadily increased in number.  The gallbladder sludge was identified in 1 patient 34 months after commencing treatment and did not progress to gallstones during the study period (52 months).
In the present study, we observed GI side effects ranging from bloating and flatulence in all patients and diarrhoea in 57% of the patients. These complaints were self-limiting in all patients. In a study by Johan A Verhelst et al. on 66 patients, GI complaints were reported by 41 patients (62%).  Most prominent problems were diarrhoea, loose stools, abdominal cramps, and nausea, which were self-limiting. We observed gall stones in 71% of our patients. This proportion of gall stones prevalence is higher than that reported from the West (11-34%). Only one study by Moschetta et al. reported a very high incidence of gallstones in six of seven patients (85%) within 8 months of therapy.  Indian diet includes a higher proportion of carbohydrates and fats unlike the high-protein diet of the west. Gall bladder motility and function is proportional to the fat intake. It is possible that inhibition of gall bladder motility by octreotide in dynamic gall bladder as in Indians could cause a high proportion of gallstones.
In conclusion, we report a high incidence of gallstones with octreotide in acromegalic patients as compared to the western population. The reasons for this discrepancy are unclear.
| References|| |
|1.||Melmed S. Acromegaly. In: Leslie J, Degroot J, Jameson L, editors. Endocrinology. 6 th ed., vol. 1. Philadelphia: WB Saunders; 2010. |
|2.||Thomas LA, Veysey MJ, Bathgate T, King A, French G, Smeeton NC, et al. Mechanism for the transit-induced increase in colonic deoxycholic acid formation in cholesterol cholelithiasis. Gastroenterology 2000;119:806-15. |
|3.||Turner HE, Lindsell DR, Vadivale A, Thillainayagam AV, Wass JA. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly. Eur J Endocrinol 1999;141:590-4. |
|4.||Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22. |
|5.||Yang LP, Keating GM. Octreotide long-acting release (LAR): A review of its use in the management of acromegaly. Drugs 2010;70:1745-69. |
|6.||Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: Results of a multicenter trial in 103 patients-A clinical research center study. J Clin Endocrinol Metab 1995;80:2768-75. |
|7.||Thomas LA, Veysey MJ, Murphy GM, Russell-Jones D, French GL, Wass JA, et al. Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly. Gut 2005;54:630-5. |
|8.||Hussaini SH, Pereira SP, Murphy GM, Kennedy C, Wass JA, Besser GM, et al. Composition of gall bladder stones associated with octreotide: Response to oral ursodeoxycholic acid. Gut 1995;36:126-32 |
|9.||Hussaini SH, Pereira SP, Veysey MJ, Kennedy C, Jenkins P, Murphy GM, et al. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Gut 1996;38:775-83. |
|10.||Lewis SJ, Heaton KW. The metabolic consequences of slow colonic transit. Am J Gastroenterol 1999;94:2010-6. |
|11.||Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, et al. Lanreotide 60 mg, a new long-acting formulation: Effectiveness in the chronictreatment of acromegaly. J Clin Endocrinol Metab 2003;88:5258-65. |
|12.||Catnach SM, Anderson JV, Fairclough PD, Trembath RC, Wilson PA, Parker E, et al. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly. Gut 1993;34:270-3. |
|13.||Moschetta A, Stolk MF, Rehfeld JF, Portincasa P, Slee PH, Koppeschaar HP, et al. Severe impairment of postprandial cholecystokinin release and gall-bladderemptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 2001;15:181-5. |
|14.||Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for thetreatment of acromegaly. J Clin Endocrinol Metab 2002;87:4142-6. |
|15.||Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, et al. Slow-release lanreotide in the treatment of acromegaly: A study in 66 patients. Eur J Endocrinol 2000;143:577-84. |
[Table 1], [Table 2]